ProfileGDS5678 / 1438358_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 57% 58% 56% 56% 57% 59% 61% 57% 57% 57% 57% 57% 57% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5663459
GSM967853U87-EV human glioblastoma xenograft - Control 23.4607357
GSM967854U87-EV human glioblastoma xenograft - Control 33.4749758
GSM967855U87-EV human glioblastoma xenograft - Control 43.3512656
GSM967856U87-EV human glioblastoma xenograft - Control 53.3750556
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5544757
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.645159
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6360461
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4349257
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4237157
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4665657
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4280357
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4664857
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4679157